{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T20:45:41Z","timestamp":1781815541721,"version":"3.54.5"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.drugalcdep.2018.04.028","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T23:05:02Z","timestamp":1527807902000},"page":"96-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Review: Adjunctive pharmacologic approaches for benzodiazepine tapers"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-744X","authenticated-orcid":false,"given":"Justine W.","family":"Welsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Tretyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Kathryn","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivera","family":"Bogunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0005","series-title":"Diagnostic and Statistical Manual","author":"American Psychiatric Association","year":"1980"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American sychiatric Association","year":"2013"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0020","first-page":"411","article-title":"Flumazenil in benzodiazepine antagonism. Actions and clinical use in intoxications and anaesthesiology","volume":"2","author":"Amrein","year":"1987","journal-title":"Med. Toxicol. Adverse Drug Exp."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0025","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1360-0443.1987.tb01529.x","article-title":"Benzodiazepine withdrawal: outcome in 50 patients","volume":"82","author":"Ashton","year":"1987","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1192\/bjp.157.2.232","article-title":"A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users","volume":"157","author":"Ashton","year":"1990","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/15622975.2015.1048725","article-title":"Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo-controlled, blinded trial","volume":"17","author":"Baandrup","year":"2016","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/026988119801200205","article-title":"Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users","volume":"12","author":"Bernik","year":"1998","journal-title":"J. Psychopharmacol."},{"issue":"27","key":"10.1016\/j.drugalcdep.2018.04.028_bib0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eurpsy.2010.12.004","article-title":"Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice","author":"Bobes","year":"2012","journal-title":"Eur. Psychiatry J. Assoc. Eur. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0050","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1517\/14656566.2012.699523","article-title":"Off-label uses of trazodone: a review","volume":"13","author":"Bossini","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00004714-199602000-00009","article-title":"Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with severe benzodiazepine dependence","volume":"16","author":"Busto","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.156.3.406","article-title":"Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal","volume":"156","author":"Cantopher","year":"1990","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0065","series-title":"Results from the 2015 National Survey on Drug Use and Health: Detailed Tables","author":"Center for Behavioral Health Statistics and Quality","year":"2016"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0070","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/00952990802149021","article-title":"Oxcarbazepine in rapid benzodiazepine detoxification","volume":"34","author":"Croissant","year":"2008","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00213-002-1376-8","article-title":"Benzodiazepines: more \u201cbehavioural\u201d addiction than dependence","volume":"167","author":"de las Cuevas","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-199502000-00003","article-title":"Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study","volume":"15","author":"Delle Chiaie","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.drugalcdep.2018.04.028_bib0085","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005194.pub2","article-title":"Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings","author":"Denis","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0090","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/ajp.144.3.303","article-title":"Discontinuation of alprazolam treatment in panic patients","volume":"144","author":"Fyer","year":"1987","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02219713","article-title":"Treatment of benzodiazepine withdrawal symptoms with carbamazepine","volume":"241","author":"Garcia-Borreguero","year":"1991","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0100","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/archinte.159.20.2456","article-title":"Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach","volume":"159","author":"Garfinkel","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0011-393X(05)80679-4","article-title":"Effectiveness of flumazenil (RO 15-1788) in the treatment of benzodiazepine withdrawal","volume":"54","author":"Gerra","year":"1993","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/1355621021000005973","article-title":"Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study","volume":"7","author":"Gerra","year":"2002","journal-title":"Addict. Biol."},{"issue":"62","key":"10.1016\/j.drugalcdep.2018.04.028_bib0115","first-page":"225","article-title":"Meta-analysis of benzodiazepine use in the treatment of insomnia","author":"Holbrook","year":"2000","journal-title":"CMAJ 1"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0120","series-title":"Overview, Key Findings on Adolescent Drug Use","article-title":"Monitoring the future national survey results on drug use","author":"Johnston","year":"2016"},{"issue":"40","key":"10.1016\/j.drugalcdep.2018.04.028_bib0125","first-page":"862","article-title":"Benzodiazepines-- their role in aggression and why GPs should prescribe with caution","author":"Jones","year":"2011","journal-title":"Aust. Fam. Physician"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1507\/endocrj1954.33.405","article-title":"Nocturnal enhancement of plasma melatonin could be suppressed by benzodiazepines in humans","volume":"33","author":"Kabuto","year":"1986","journal-title":"Endocrinol. Jpn."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0135","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1176\/ajp.151.12.1760","article-title":"Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine","volume":"151","author":"Klein","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0140","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1530-0277.2007.00419.x","article-title":"Oxcarbazepine--efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study","volume":"31","author":"Koethe","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0145","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s11606-016-3740-0","article-title":"Benzodiazepines are prescribed more frequently to patients already at risk for benzodiazepine-related adverse events in primary care","volume":"31","author":"Kroll","year":"2016","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0150","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11920-015-0642-5","article-title":"Withdrawing benzodiazepines in patients with anxiety disorders","volume":"18","author":"Lader","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/026988119200600303","article-title":"A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal","volume":"6","author":"Lader","year":"1992","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-198702000-00003","article-title":"A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms","volume":"7","author":"Lader","year":"1987","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/0023210-200923010-00002","article-title":"Withdrawing benzodiazepines in primary care","volume":"23","author":"Lader","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0170","doi-asserted-by":"crossref","first-page":"e0142057","DOI":"10.1371\/journal.pone.0142057","article-title":"High-dose benzodiazepine dependence: a qualitative study of patients\u2019 perceptions on initiation, reasons for use, and obtainment","volume":"10","author":"Liebrenz","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","article-title":"Buspirone: what is it all about?","volume":"1461","author":"Loane","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0180","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","article-title":"Benzodiazepine use in older adults: dangers, management, and alternative therapies","volume":"91","author":"Markota","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0185","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s002130051161","article-title":"A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users","volume":"147","author":"Mintzer","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0190","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1440-1819.2006.01565.x","article-title":"Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic","volume":"60","author":"Nakao","year":"2006","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0195","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1176\/ajp.148.4.517","article-title":"Controlled discontinuation of benzodiazepine treatment for patients with panic disorder","volume":"148","author":"Noyes","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0200","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archpsyc.1990.01810220033004","article-title":"Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder","volume":"47","author":"Nutt","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0205","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1176\/ajp.150.10.1485","article-title":"Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder","volume":"150","author":"Otto","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0210","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.brat.2010.04.002","article-title":"Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluation","volume":"48","author":"Otto","year":"2010","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0215","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/(SICI)1099-1166(199909)14:9<754::AID-GPS15>3.0.CO;2-E","article-title":"A programme for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: Success rate and effect on subjective sleep quality","volume":"14","author":"Petrovic","year":"1999","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0220","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archpsyc.1990.01810220015002","article-title":"Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation","volume":"47","author":"Rickels","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0225","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1097\/00004714-199912002-00003","article-title":"Pharmacologic strategies for discontinuing benzodiazepine treatment","volume":"19","author":"Rickels","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130050798","article-title":"Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome","volume":"141","author":"Rickels","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0235","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1176\/appi.ajp.157.12.1973","article-title":"Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy","volume":"157","author":"Rickels","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0240","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1176\/ajp.146.4.536","article-title":"Carbamazepine treatment for benzodiazepine withdrawal","volume":"146","author":"Ries","year":"1989","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/01.jcp.0000088907.24613.3f","article-title":"Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy","volume":"23","author":"Rynn","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0250","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archpsyc.1991.01810290060012","article-title":"Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome","volume":"48","author":"Schweizer","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0255","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF02246214","article-title":"Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome","volume":"117","author":"Schweizer","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0260","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.genhosppsych.2006.05.008","article-title":"Outcome of new benzodiazepine prescriptions to older adults in primary care","volume":"28","author":"Simon","year":"2006","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0265","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJMra1611832","article-title":"Treatment of benzodiazepine dependence","volume":"376","author":"Soyka","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0270","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/ajp.151.6.876","article-title":"Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder?","volume":"151","author":"Spiegel","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0275","series-title":"The DAWN Report: Benzodiazepines in Combination With Opioid Pain Relievers or Alcohol: Greater Risk of More Serious ED Visit Outcomes","article-title":"Center for behavioral health statistics and quality","author":"Substance Abuse and Mental Health Services Administration","year":"2014"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0280","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0140-6736(81)92861-0","article-title":"Benzodiazepine withdrawal symptoms and propranolol","volume":"1","author":"Tyrer","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0285","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/bjp.182.6.498","article-title":"Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: Three-condition, randomised controlled trial","volume":"182","author":"Voshaar","year":"2003","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0290","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1192\/bjp.189.3.213","article-title":"Strategies for discontinuing long-term benzodiazepine use: meta-analysis","volume":"189","author":"Voshaar","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0295","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/070674370605100706","article-title":"Predictors of long-term benzodiazepine abstinence in participants of a randomized controlled benzodiazepine withdrawal program","volume":"51","author":"Voshaar","year":"2006","journal-title":"Can. J. Psychiatry Rev."},{"key":"10.1016\/j.drugalcdep.2018.04.028_bib0300","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1192\/bjp.178.4.317","article-title":"Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch chronic benzodiazepine working group","volume":"178","author":"Zitman","year":"2001","journal-title":"Br. J. Psychiatry"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618302953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618302953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:55:33Z","timestamp":1759827333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871618302953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":60,"alternative-id":["S0376871618302953"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.04.028","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review: Adjunctive pharmacologic approaches for benzodiazepine tapers","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}